Vertex Net Income Per E B T from 2010 to 2024

VRTX Stock  USD 468.13  3.57  0.77%   
Vertex Pharmaceuticals Net Income Per E B T yearly trend continues to be fairly stable with very little volatility. Net Income Per E B T will likely drop to 0.73 in 2024. During the period from 2010 to 2024, Vertex Pharmaceuticals Net Income Per E B T regression line of annual values had significance of  0.69 and arithmetic mean of  0.40. View All Fundamentals
 
Net Income Per E B T  
First Reported
2010-12-31
Previous Quarter
0.82643043
Current Value
0.73
Quarterly Volatility
5.18942482
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 10.4 B, Gross Profit of 9 B or Other Operating Expenses of 6.3 B, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.46. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Net Income Per E B T Growth Pattern

Below is the plot of the Net Income Per E B T of Vertex Pharmaceuticals over the last few years. It is Vertex Pharmaceuticals' Net Income Per E B T historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income Per E B T10 Years Trend
Pretty Stable
   Net Income Per E B T   
       Timeline  

Vertex Net Income Per E B T Regression Statistics

Arithmetic Mean0.40
Coefficient Of Variation1,313
Mean Deviation2.29
Median0.86
Standard Deviation5.19
Sample Variance26.93
Range25.439
R-Value(0.11)
Mean Square Error28.63
R-Squared0.01
Significance0.69
Slope(0.13)
Total Sum of Squares377.02

Vertex Net Income Per E B T History

2024 0.73
2023 0.83
2022 0.78
2021 0.86
2020 0.87
2019 0.84
2018 3.49

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Net Income Per E B T, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income Per E B T 0.83  0.73 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.